XLO Overview

Quarterly Performance: Xilio Therapeutics reported a quarterly loss of $0.03 per share, matching expectations, and significantly improved from a loss of $0.22 per share a year ago, while revenues of $19.07 million fell short of estimates by 28.51%.

Stock Outlook: The company's shares have declined by 19% this year, contrasting with the S&P 500's 16.5% gain, and the stock currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.

Earnings Estimates: The consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, with a fiscal year estimate of -$0.45 on $45.65 million in revenues, reflecting mixed trends in earnings estimate revisions.

Industry Context: Xilio operates within the Medical - Biomedical and Genetics industry, which ranks in the top 35% of Zacks industries, suggesting that industry performance could significantly influence the stock's future.

Clinical Trial Results: Xilio Therapeutics reported a 40% objective response rate (ORR) in heavily pre-treated patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without liver metastases and high plasma tumor mutational burden (TMB) in their Phase 2 trial of vilastobart combined with atezolizumab.

Plasma TMB as a Biomarker: Approximately 55% of patients with MSS CRC are estimated to have high plasma TMB, indicating a significant population that may benefit from the combination treatment, highlighting the potential of plasma-based TMB as a predictive biomarker for response.

Safety Profile: The combination therapy of vilastobart and atezolizumab demonstrated a well-tolerated safety profile, with most treatment-related adverse events being Grade 1 or 2, and only a small percentage of patients discontinuing treatment due to adverse effects.

Future Plans: Xilio is seeking partnerships to further develop vilastobart in combination with PD-(L)1 or PD1-VEGF therapies for MSS CRC and other tumor types, following the promising results from the clinical trial.

Xilio Therapeutics Presentation: Xilio Therapeutics will present a late-breaking poster on vilastobart, an anti-CTLA-4 therapy, at the SITC 40th Annual Meeting from November 5-9, 2025, focusing on its efficacy in metastatic colorectal cancer patients with high plasma tumor mutational burden.

Poster Details: The poster, titled "Plasma Tumor Mutational Burden (pTMB) Enriched for Response to Vilastobart in Combination with Atezolizumab," will be presented on November 7, 2025, and will be available on Xilio's website.

Company Overview: Xilio Therapeutics is a clinical-stage biotechnology firm developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects.

Forward-Looking Statements: The press release includes cautionary notes regarding forward-looking statements, highlighting potential risks and uncertainties related to Xilio's clinical programs and business operations.